RPRX Annual Cash & Cash Equivalents
$477.01 M
-$1.23 B-72.12%
31 December 2023
Summary:
As of January 22, 2025, RPRX annual cash & cash equivalents is $477.01 million, with the most recent change of -$1.23 billion (-72.12%) on December 31, 2023. During the last 3 years, it has fallen by -$531.67 million (-52.71%). RPRX annual cash & cash equivalents is now -75.21% below its all-time high of $1.92 billion, reached on December 31, 2018.RPRX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RPRX Quarterly Cash And Cash Equivalents
$950.05 M
-$814.59 M-46.16%
30 September 2024
Summary:
As of January 22, 2025, RPRX quarterly cash and cash equivalents is $950.05 million, with the most recent change of -$814.59 million (-46.16%) on September 30, 2024. Over the past year, it has increased by +$107.05 million (+12.70%). RPRX quarterly cash and cash equivalents is now -61.12% below its all-time high of $2.44 billion, reached on June 30, 2020.RPRX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RPRX Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -72.1% | +12.7% |
| 3 y3 years | -52.7% | +12.7% |
| 5 y5 years | -75.2% | - |
RPRX Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -72.1% | at low | -56.3% | +99.2% |
| 5 y | 5-year | -72.1% | +93.8% | -61.1% | +285.9% |
| alltime | all time | -75.2% | +93.8% | -61.1% | +285.9% |
Royalty Pharma Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $950.05 M(-46.2%) |
| June 2024 | - | $1.76 B(+109.3%) |
| Mar 2024 | - | $843.00 M(+76.7%) |
| Dec 2023 | $477.01 M(-72.1%) | $477.01 M(-49.1%) |
| Sept 2023 | - | $936.45 M(-56.9%) |
| June 2023 | - | $2.17 B(+10.0%) |
| Mar 2023 | - | $1.98 B(+15.5%) |
| Dec 2022 | $1.71 B | $1.71 B(+72.5%) |
| Sept 2022 | - | $991.63 M(-53.0%) |
| June 2022 | - | $2.11 B(+17.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $1.79 B(+16.3%) |
| Dec 2021 | $1.54 B(+52.8%) | $1.54 B(-14.4%) |
| Sept 2021 | - | $1.80 B(+57.7%) |
| June 2021 | - | $1.14 B(+61.2%) |
| Mar 2021 | - | $708.81 M(-29.7%) |
| Dec 2020 | $1.01 B(+309.7%) | $1.01 B(-35.0%) |
| Sept 2020 | - | $1.55 B(-36.4%) |
| June 2020 | - | $2.44 B(+291.3%) |
| Mar 2020 | - | $624.37 M(+153.6%) |
| Dec 2019 | $246.20 M(-87.2%) | $246.20 M |
| Dec 2018 | $1.92 B | - |
FAQ
- What is Royalty Pharma annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Royalty Pharma?
- What is Royalty Pharma annual cash & cash equivalents year-on-year change?
- What is Royalty Pharma quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Royalty Pharma?
- What is Royalty Pharma quarterly cash and cash equivalents year-on-year change?
What is Royalty Pharma annual cash & cash equivalents?
The current annual cash & cash equivalents of RPRX is $477.01 M
What is the all time high annual cash & cash equivalents for Royalty Pharma?
Royalty Pharma all-time high annual cash & cash equivalents is $1.92 B
What is Royalty Pharma annual cash & cash equivalents year-on-year change?
Over the past year, RPRX annual cash & cash equivalents has changed by -$1.23 B (-72.12%)
What is Royalty Pharma quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of RPRX is $950.05 M
What is the all time high quarterly cash and cash equivalents for Royalty Pharma?
Royalty Pharma all-time high quarterly cash and cash equivalents is $2.44 B
What is Royalty Pharma quarterly cash and cash equivalents year-on-year change?
Over the past year, RPRX quarterly cash and cash equivalents has changed by +$107.05 M (+12.70%)